News Y-mAbs Therapeutics, Inc.

Equities

YMAB

US9842411095

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
15.13 ^USD	+0.87%		+5.29%	+121.85%

Mar. 14	Y-mAbs Therapeutics Chief Financial Officer Bo Kruse to Resign	MT
Mar. 14	Y-mAbs Therapeutics, Inc. Announces Resignation of Bo Kruse as Executive Vice President, Secretary and Treasurer, Effective July 31, 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Y-mAbs Therapeutics Chief Financial Officer Bo Kruse to Resign	Mar. 14	MT
Y-mAbs Therapeutics, Inc. Announces Resignation of Bo Kruse as Executive Vice President, Secretary and Treasurer, Effective July 31, 2024	Mar. 14	CI
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer	Mar. 14	AQ
Y-mAbs Therapeutics Announces Resignation of Bo Kruse as Chief Financial Officer	Mar. 14	CI
HC Wainwright Adjusts Price Target on Y-mAbs Therapeutics to $22 From $21, Keeps Buy Rating	Mar. 06	MT
Canaccord Genuity Raises Price Target on Y-mAbs Therapeutics to $26 From $22, Maintains Buy Rating	Mar. 04	MT
BMO Capital Adjusts Y-mAbs Therapeutics Price Target to $26 From $16, Maintains Outperform Rating	Mar. 04	MT
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors	Mar. 04	AQ
Y-mAbs Therapeutics, Inc. Appoints Mary Tagliaferri to Its Board of Directors	Mar. 04	CI
Y mAbs Therapeutics : mAbs Appoints Oncolog Executive Mar Tagliaferri, M.D. to its Board of Directors - Form 8-K	Mar. 04	PU
Wedbush Raises Y-mAbs Therapeutics' PT to $23 From $18 After Higher-Than-Expected Q4 2023 Danyelza Net Product Revenue, Maintains Outperform Rating	Mar. 04	MT
Transcript : Y-mAbs Therapeutics, Inc., Q4 2023 Earnings Call, Mar 01, 2024	Mar. 01
Y-mAbs Therapeutics Surges 18% in Premarket Activity Following Q4 Results; Reiterates Anticipated Cash Runway into 2027	Mar. 01	MT
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Earnings Flash (YMAB) Y-MABS THERAPEUTICS Reports Q4 Revenue $23.4M, vs. Street Est of $21M	Feb. 29	MT
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments	Feb. 29	AQ
Y-mAbs Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	Feb. 29	CI
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024 (Updated)	Feb. 21	AQ
HC Wainwright Adjusts Y-mAbs Therapeutics Price Target to $21 From $11, Maintains Buy Rating	Feb. 20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Y-mAbs Therapeutics, Inc.

Equities

YMAB

US9842411095

Summary

Filters